Recursion Pharmaceuticals (RXRX) Receivables (2020 - 2022)

Recursion Pharmaceuticals has reported Receivables for 3 years, with the latest figure at $2.8 million in Q4 2022.

• For the quarter ending Q4 2022, Receivables fell 69.71% year-over-year to $2.8 million; the trailing twelve-month figure through Dec 2022 stood at $2.8 million (down 69.71% YoY), and the FY2022 full-year result was $2.8 million, down 69.71% from the prior year.
• Receivables for Q4 2022 stood at $2.8 million, down from $11.6 million in the prior quarter.
• The five-year high for Receivables was $11.7 million in Q2 2022, with the low at $49000.0 in Q2 2021.
• Historically, Receivables has averaged $5.5 million across 3 years, with a median of $2.8 million in 2022.
• The largest YoY upside for Receivables was 23736.73% in 2022 against a maximum downside of 69.71% in 2022.
• Recursion Pharmaceuticals' Receivables stood at $156000.0 in 2020, then soared by 5726.92% to $9.1 million in 2021, then sank by 69.71% to $2.8 million in 2022.
• The last three Receivables figures came in at $2.8 million (Q4 2022), $11.6 million (Q3 2022), and $11.7 million (Q2 2022), per Business Quant data.